Kory J. Wentworth's Insider Trades & SAST Disclosures
Kory J. Wentworth's most recent trade in Entrada Therapeutics Inc was a trade of 1,784 Common Stock done at an average price of $10.7 . Disclosure was reported to the exchange on March 17, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Kory J. Wentworth.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 10.67 per share. | 17 Mar 2025 | 1,784 | 109,536 | - | 10.7 | 19,035 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 63,300 | 63,300 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 42,400 | 116,249 | - | 0 | Common Stock | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.68 per share. | 01 Mar 2025 | 4,929 | 111,320 | - | 11.7 | 57,564 | Common Stock |
| Entrada Therapeutics Inc | Wentworth Kory J. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 29 Nov 2024 | 5,000 | 78,849 | - | 2.1 | 10,500 | Common Stock |
| Entrada Therapeutics Inc | J. Kory Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2024 | 5,000 | 31,157 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory Wentworth J. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 29 Nov 2024 | 5,000 | 73,849 | - | 20.0 | 99,978 | Common Stock |
| Entrada Therapeutics Inc | J. Kory Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2024 | 1,000 | 36,157 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | J. Kory Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 29 Nov 2024 | 1,000 | 74,849 | - | 2.1 | 2,100 | Common Stock |
| Entrada Therapeutics Inc | Wentworth Kory J. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.97 per share. | 29 Nov 2024 | 1,000 | 73,849 | - | 20.0 | 19,970 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.98 per share. | 11 Nov 2024 | 8,637 | 73,849 | - | 20.0 | 172,562 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2024 | 6,000 | 37,157 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 11 Nov 2024 | 6,000 | 82,486 | - | 2.1 | 12,600 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.97 per share. | 09 Sep 2024 | 3,195 | 76,486 | - | 15.0 | 47,832 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.42 per share. | 03 Sep 2024 | 941 | 79,846 | - | 15.4 | 14,513 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.76 per share. | 03 Sep 2024 | 462 | 80,950 | - | 15.8 | 7,282 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.13 per share. | 03 Sep 2024 | 165 | 79,681 | - | 15.1 | 2,496 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.93 per share. | 03 Sep 2024 | 149 | 80,801 | - | 16.9 | 2,522 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.71 per share. | 03 Sep 2024 | 14 | 80,787 | - | 17.7 | 248 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.95 per share. | 08 Jul 2024 | 1,758 | 81,412 | - | 14.9 | 26,282 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 9,000 | 43,157 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 15 Mar 2024 | 9,000 | 83,170 | - | 2.1 | 18,900 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.31 per share. | 06 Mar 2024 | 4,086 | 74,170 | - | 12.3 | 50,285 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 46,800 | 46,800 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 30,900 | 80,471 | - | 0 | Common Stock | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.28 per share. | 01 Mar 2024 | 1,471 | 78,256 | - | 12.3 | 18,062 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.37 per share. | 01 Mar 2024 | 405 | 79,727 | - | 13.4 | 5,414 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.42 per share. | 01 Mar 2024 | 339 | 80,132 | - | 12.4 | 4,211 | Common Stock |
| Entrada Therapeutics Inc | Kory Wentworth J. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 21 Dec 2023 | 10,206 | 59,777 | - | 2.1 | 21,433 | Common Stock |
| Entrada Therapeutics Inc | Kory Wentworth J. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2023 | 10,206 | 52,251 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | J. Kory Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.24 per share. | 21 Dec 2023 | 6,529 | 53,248 | - | 15.2 | 99,513 | Common Stock |
| Entrada Therapeutics Inc | Wentworth Kory J. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.48 per share. | 21 Dec 2023 | 3,677 | 49,571 | - | 16.5 | 60,611 | Common Stock |
| Entrada Therapeutics Inc | Kory Wentworth J. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2023 | 2,200 | 62,457 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 21 Dec 2023 | 2,200 | 51,771 | - | 2.1 | 4,620 | Common Stock |
| Entrada Therapeutics Inc | Wentworth J. Kory | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.07 per share. | 21 Dec 2023 | 2,200 | 49,571 | - | 15.1 | 33,155 | Common Stock |
| Entrada Therapeutics Inc | Wentworth J. Kory | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2023 | 94 | 52,157 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | J. Wentworth Kory | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 21 Dec 2023 | 94 | 49,665 | - | 2.1 | 197 | Common Stock |
| Entrada Therapeutics Inc | Wentworth Kory J. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.67 per share. | 21 Dec 2023 | 94 | 49,571 | - | 16.7 | 1,567 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.98 per share. | 10 Jul 2023 | 6,116 | 36,747 | - | 18.0 | 109,958 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2023 | 6,116 | 68,541 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 10 Jul 2023 | 6,116 | 42,863 | - | 2.1 | 12,844 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2023 | 3,884 | 64,657 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 10 Jul 2023 | 3,884 | 36,747 | - | 18.0 | 69,904 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 10 Jul 2023 | 3,884 | 40,631 | - | 2.1 | 8,156 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2023 | 8,790 | 74,657 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 29 Jun 2023 | 8,790 | 36,747 | - | 2.1 | 18,459 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 21 Jun 2023 | 17,500 | 45,457 | - | 2.1 | 36,750 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2023 | 17,500 | 83,447 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.17 per share. | 21 Jun 2023 | 8,907 | 27,957 | - | 15.2 | 135,129 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.84 per share. | 21 Jun 2023 | 8,593 | 36,864 | - | 14.8 | 127,519 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 21,500 | 21,500 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 14,200 | 27,957 | - | 0 | Common Stock | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.95 per share. | 08 Dec 2022 | 4,550 | 16,509 | - | 19.0 | 86,238 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2022 | 4,550 | 100,947 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 08 Dec 2022 | 4,550 | 21,059 | - | 2.1 | 9,555 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 02 Dec 2022 | 2,910 | 19,419 | - | 2.1 | 6,111 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 2,910 | 105,697 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.20 per share. | 02 Dec 2022 | 2,910 | 16,509 | - | 18.2 | 52,949 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 200 | 105,497 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.05 per share. | 02 Dec 2022 | 200 | 16,509 | - | 18.1 | 3,610 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 02 Dec 2022 | 200 | 16,709 | - | 2.1 | 420 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 16 Nov 2022 | 200 | 16,709 | - | 2.1 | 420 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2022 | 200 | 108,607 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.10 per share. | 16 Nov 2022 | 200 | 16,509 | - | 18.1 | 3,620 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 5,503 | 16,489 | - | 0 | Common Stock | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.52 per share. | 24 Aug 2022 | 2,817 | 12,838 | - | 13.5 | 38,093 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.18 per share. | 24 Aug 2022 | 1,551 | 10,986 | - | 14.2 | 21,986 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Aug 2022 | 1,117 | 108,807 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 24 Aug 2022 | 1,117 | 15,655 | - | 2.1 | 2,346 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.23 per share. | 24 Aug 2022 | 301 | 12,537 | - | 14.2 | 4,282 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.08 per share. | 19 Aug 2022 | 8,529 | 16,144 | - | 13.1 | 111,530 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2022 | 4,452 | 111,444 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 19 Aug 2022 | 4,452 | 24,673 | - | 2.1 | 9,349 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.09 per share. | 19 Aug 2022 | 2,909 | 14,538 | - | 13.1 | 38,080 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2022 | 1,403 | 109,924 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 19 Aug 2022 | 1,403 | 17,447 | - | 2.1 | 2,946 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 19 Aug 2022 | 217 | 16,044 | - | 13.0 | 2,822 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2022 | 117 | 111,327 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 19 Aug 2022 | 117 | 16,261 | - | 2.1 | 246 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 16 Aug 2022 | 200 | 20,221 | - | 13 | 2,600 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.07 per share. | 16 Aug 2022 | 200 | 20,341 | - | 13.1 | 2,614 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 16 Aug 2022 | 200 | 20,441 | - | 13 | 2,600 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2022 | 100 | 115,896 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2022 | 100 | 115,996 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2022 | 100 | 116,096 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 16 Aug 2022 | 100 | 20,441 | - | 2.1 | 210 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 16 Aug 2022 | 100 | 20,541 | - | 2.1 | 210 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 16 Aug 2022 | 100 | 20,641 | - | 2.1 | 210 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 33,019 | 33,019 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 66,038 | 66,038 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 11,006 | 20,541 | - | 0 | Common Stock | |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 72,012 | 72,012 | - | - | Stock Option (Right to Buy) | |
| Bluebird bio Inc | Kory J. Wentworth | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 61.00 per share. | 03 Aug 2020 | 82 | 9,512 (0%) | 0% | 61 | 5,002 | Common Stock |
| Bluebird bio Inc | Kory J. Wentworth | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 66.38 per share. | 20 Jul 2020 | 596 | 9,594 (0%) | 0% | 66.4 | 39,562 | Common Stock |
| Bluebird bio Inc | Kory J. Wentworth | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 65.01 per share. | 04 Jun 2020 | 92 | 10,252 (0%) | 0% | 65.0 | 5,981 | Common Stock |
| Bluebird bio Inc | Kory J. Wentworth | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 65.56 per share. | 04 Jun 2020 | 62 | 10,190 (0%) | 0% | 65.6 | 4,065 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges